GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A

Adenosine A2 Receptor Antagonists / chemistry Crystallography, X-Ray Molecular Conformation Nucleosides Receptor, Adenosine A2A / chemistry Thiophenes

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
08 09 2022
Historique:
pubmed: 18 8 2022
medline: 11 9 2022
entrez: 17 8 2022
Statut: ppublish

Résumé

Modulators of the G protein-coupled A

Identifiants

DOI: 10.1021/acs.jmedchem.2c00462 PMID: 35977382 PMC: PMC9469204
pubmed: 35977382
doi: 10.1021/acs.jmedchem.2c00462
pmc: PMC9469204
doi:

Substances chimiques

Adenosine A2 Receptor Antagonists 0
Nucleosides 0
Receptor, Adenosine A2A 0
Thiophenes 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

11648-11657

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM138396
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM127086
Pays : United States
Organisme : NIH HHS
ID : S10 OD012289
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA DK031117
Pays : United States

Références

J Org Chem. 2000 Jun 2;65(11):3432-42
pubmed: 10843627
Front Pharmacol. 2017 Dec 01;8:888
pubmed: 29249971
Science. 2011 Apr 15;332(6027):322-7
pubmed: 21393508
Nat Protoc. 2009;4(5):706-31
pubmed: 19390528
Lancet Neurol. 2003 Jun;2(6):366-74
pubmed: 12849153
Science. 2008 Nov 21;322(5905):1211-7
pubmed: 18832607
Trends Pharmacol Sci. 2018 Jan;39(1):75-89
pubmed: 29203139
J Med Chem. 2018 Jan 11;61(1):1-46
pubmed: 28657745
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2066-2071
pubmed: 28167788
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Comput Struct Biotechnol J. 2015 Apr 08;13:265-72
pubmed: 25941561
J Med Chem. 2011 Jul 14;54(13):4312-23
pubmed: 21661720
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
J R Soc Interface. 2009 Oct 6;6 Suppl 5:S587-97
pubmed: 19535414
Pharmacol Rev. 2001 Dec;53(4):527-52
pubmed: 11734617
Science. 2012 Jul 13;337(6091):232-6
pubmed: 22798613
J Med Chem. 2021 Sep 9;64(17):12525-12536
pubmed: 34435786
J Med Chem. 2014 May 8;57(9):3623-50
pubmed: 24164628
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Bioorg Med Chem. 2009 May 15;17(10):3733-8
pubmed: 19375920
J Med Chem. 2012 Jan 12;55(1):342-56
pubmed: 22142423
J Comput Chem. 2008 Aug;29(11):1859-65
pubmed: 18351591
J Chem Inf Model. 2012 Dec 21;52(12):3144-54
pubmed: 23146088
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32727810
J Pharmacol Exp Ther. 2009 Apr;329(1):2-13
pubmed: 19141710
Eur J Med Chem. 2021 Mar 15;214:113233
pubmed: 33550179
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):368-80
pubmed: 22505257
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Chem Rev. 2007 Mar;107(3):874-922
pubmed: 17305399
Curr Opin Struct Biol. 2019 Apr;55:147-153
pubmed: 31102980
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Neurology. 2008 Jan 15;70(3):231-6
pubmed: 18195269
Med Res Rev. 2018 Jul;38(4):1031-1072
pubmed: 28682469
IUCrJ. 2020 Oct 15;7(Pt 6):976-984
pubmed: 33209312
Nature. 2011 May 18;474(7352):521-5
pubmed: 21593763
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
J Comput Chem. 2013 Sep 30;34(25):2135-45
pubmed: 23832629
J Comput Chem. 2014 Oct 15;35(27):1997-2004
pubmed: 25130509
Sci Rep. 2018 Jan 8;8(1):41
pubmed: 29311713
Trends Neurosci. 2006 Nov;29(11):647-54
pubmed: 17030429
Structure. 2017 Aug 1;25(8):1275-1285.e4
pubmed: 28712806

Auteurs

Anna Shiriaeva (A)

Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.
Bridge Institute, University of Southern California, Los Angeles, California 90089, United States.

Daejin Park (D)

Department of Pharmacology, Kosin University College of Medicine, Busan 49267, Republic of Korea.

Gyudong Kim (G)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
College of Pharmacy & Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea.
ORCID: 0000-0002-4894-951X

Yoonji Lee (Y)

College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
ORCID: 0000-0002-2494-5792

Xiyan Hou (X)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.

Dnyandev B Jarhad (DB)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.

Gibae Kim (G)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.

Jinha Yu (J)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.

Young Eum Hyun (YE)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.

Woomi Kim (W)

Department of Pharmacology, Kosin University College of Medicine, Busan 49267, Republic of Korea.

Zhan-Guo Gao (ZG)

Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.

Kenneth A Jacobson (KA)

Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.
ORCID: 0000-0001-8104-1493

Gye Won Han (GW)

Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.
Bridge Institute, University of Southern California, Los Angeles, California 90089, United States.

Raymond C Stevens (RC)

Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.
Bridge Institute, University of Southern California, Los Angeles, California 90089, United States.
Structure Therapeutics, 701 Gateway Blvd, South San Francisco, California 94080, United States.

Lak Shin Jeong (LS)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
ORCID: 0000-0002-3441-707X

Sun Choi (S)

Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
ORCID: 0000-0002-7669-7954

Vadim Cherezov (V)

Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.
Bridge Institute, University of Southern California, Los Angeles, California 90089, United States.
ORCID: 0000-0002-5265-3914

Articles similaires

Crystal structure of the HMGA AT-hook 1 domain bound to the minor groove of AT-rich DNA and inhibition by antikinetoplastid drugs.

J Jonathan Nué-Martinez, Marta Maturana, Laura Lagartera et al.
1.00
Crystallography, X-Ray DNA Protein Binding HMGA Proteins AT-Hook Motifs

Human prolyl hydroxylase domain 2 reacts with O

Giorgia Fiorini, Stephen A Marshall, William D Figg et al.
1.00
Humans Ketoglutaric Acids Hypoxia-Inducible Factor-Proline Dioxygenases Oxygen Hypoxia-Inducible Factor 1, alpha Subunit

Discovery, characterization, and synthetic potential of two novel bacterial aryl-alcohol oxidases.

Paula Cinca-Fernando, Christian Ascaso-Alegre, Emma Sevilla et al.
1.00
Alcohol Oxidoreductases Catalytic Domain Crystallography, X-Ray Substrate Specificity Recombinant Proteins

Emodin regulated lactate metabolism by inhibiting MCT1 to delay non-small cell lung cancer progression.

Fei Zhang, Tian Gu, Jin Li et al.
1.00
Monocarboxylic Acid Transporters Lung Neoplasms Emodin Humans Symporters

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents purinergiques › Antagonistes purinergiques › Antagonistes des récepteurs purinergiques P1 › Antagonistes des récepteurs A2 à l'adénosine › GPCR Agonist-to-Antagonist Conversion:...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Cristallographie aux rayons X › GPCR Agonist-to-Antagonist Conversion:...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › GPCR Agonist-to-Antagonist Conversion:...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › GPCR Agonist-to-Antagonist Conversion:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs purinergiques › Récepteurs purinergiques P1 › Récepteurs A2 à l'adénosine › Récepteur A2A à l'adénosine › GPCR Agonist-to-Antagonist Conversion:...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Thiophènes › GPCR Agonist-to-Antagonist Conversion:...